DOI:

The latest news from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)

William Wijns*, President EAPCI

As a reader of EuroIntervention Journal, percutaneous cardiovascular intervention must be your primary interest. If so, please take a few moments to read the following update news from your association, the European Association for Percutaneous Cardiovascular Interventions, known as the EAPCI.

EAPCI was formally launched at the World Congress 2006 in Barcelona as a registered branch of the European Society of cardiology. We share the ESC mission, albeit focused on our field of activity:

“To reduce the burden of cardiovascular disease in Europe

through Percutaneous Cardiovascular Interventions”

and the KEYWORDS that govern our action are:

Synergy

Focus

and Credibility.

Even though so recently born, EAPCI is already able to offer you important assets, represented by the heritage of its proud parents (EuroPCR and Working Group 10):

– EuroPCR Course, to take place this year for the first time in Barcelona, on the 22nd-25th May 2007,

– EuroPCRonline.com, featuring outstanding educational content, and the EAPCI website accessible on ESCardio.org,

– Euro Heart Survey and Registry,

– A comprehensive Education-Training-Accreditation programme,

– and not to forget, EuroIntervention Journal itself.

For EAPCI, strengths and opportunities are many. The coalition formed by the EuroPCR team – representing nearly two decades of commitment to education and teaching – along with the European Society of Cardiology – “the” representative cardiovascular medical scientific society in Europe and beyond – is a unique model. The blend of both cultures will materialise strong synergies as we consolidate our current assets and explore new activities.

At a moment where our field is experiencing another wave of expansion, leadership will be needed more than ever. To this end, EAPCI will rely entirely on a close collaboration with the national Working Groups, Societies or other bodies representing interventional communities throughout Europe, as the building blocks of our action. EAPCI can only be successful when governed by a “bottom up” relationship with its constituency.

At the beginning of the three-year term of this Board, many new initiatives are being considered, but at this present time please consider what we already have up and running right now. EAPCI leadership is structured in 8 Committees, each having a well defined mission that will be further delineated on our website and future newsletters: Communication, Euro Heart Survey, Scientific Initiatives, National Membership, Education, Fellowship, Accreditation and Clinical Initiatives. Through your national representatives, you will be asked to join and engage in these various committees, making EAPCI an essential component of your professional life in the years to come.

EAPCI Board 2006-2009.

Rows from left to right and from bottom to top,

– Marc van Sambeek, Keren Deront (EAPCI Office at ESC), Carlo Di Mario (President-Elect),

– Antoine Lafont, Sigmund Silber, Darius Dudek (Secretary),

– Martyn Thomas, Andreas Baumbach, Jean Marco, Jan-Erik Nordrehaug,

– Alberto Cremonesi, Franz Eberli, Horst Sievert (Treasurer), Franz Weidinger, William Wijns (President),

– Bernard Chevalier, Ran Kornowski, Jean Fajadet, Alec Vahanian, Alan Howard (CEO ESC).

Missing on the picture are Sally Vincent (EuroPCR office), Marc Doncieux (CEO Europa) and Patrick Serruys.

Volume 2 Number 4
Feb 20, 2007
Volume 2 Number 4
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00479 Jun 1, 2026
Valve thrombosis or valve deterioration: what truly drives the prognosis?
Waksman R and Phichaphop A
free

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al

Original Research

10.4244/EIJ-D-25-01268 Jun 1, 2026
Early outcomes of redo-TAVI with the SAPIEN 3 platform: the prospective, multicentre ReTAVI registry
Tarantini G et al

Research Correspondence

10.4244/EIJ-D-25-01160 Jun 1, 2026
First-in-human experience with a heterotopic cross-caval transcatheter tricuspid valve replacement
Estevez-Loureiro R et al

Original Research

10.4244/EIJ-D-26-00416 May 21, 2026
Long-term clinical outcomes of high-risk plaques with negative fractional flow reserve: the PECTUS-obs study
Volleberg R et al
Trending articles
87.2

State-of-the-Art

10.4244/EIJ-D-25-00266 Jan 19, 2026
Lesion stratification with intracoronary imaging
McGarvey M et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
34.8

Original Research

10.4244/EIJ-D-25-01006 Mar 16, 2026
Clinical outcomes and haemodynamic response after blinded stress assessment of moderate aortic stenosis
Eerdekens R et al
22.2

Viewpoint

10.4244/EIJ-D-25-01066 May 4, 2026
Intracoronary imaging guidance for de novo coronary lesion treatment with drug-coated balloons
Amabile N et al
free
20.75

Flashlight

10.4244/EIJ-D-25-01014 Apr 6, 2026
Stent retriever-assisted coronary thrombectomy with continuous aspiration
Liabot Q et al
open access
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
17.8

Expert Review

10.4244/EIJ-D-25-01316 Apr 20, 2026
Electrosurgical laceration and stabilisation of tricuspid edge-to-edge repair: the ELASTA-T technique
Alvarez-Covarrubias H et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved